A single arm open-label multicenter phase II study of 177Lu-DOTATATE radionuclide in adults with progressive or high-risk meningioma
Brief description of study
This single arm, open-label study will evaluate the efficacy of Lutathera (177Lu-DOTATATE) administered intravenously every 8 weeks for a total of 4 doses in patients with progressive WHO I-III or residual high-risk 68Ga-DOTATATE PET-MRI positive meningioma. 68Ga-DOTATATE MRI scans will be obtained before and 6 months after initiation of treatment .
Clinical Study Identifier: s18-00719
ClinicalTrials.gov Identifier: NCT03971461
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
